REGN
Regeneron Pharmaceuticals Inc
735.20$
+0.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 4.6% | 7.9% | 13.1% | 10.4% | 26.3% | 29.6% | 29.5% | 11.6% | 87.0% | 37.9% | 35.8% | 182.4% | 0.4% | 4.2% | 0.5% | 0.9% | 6.1% | 7.4% | 7.3% | 9.6% | 6.2% | 6.8% | 6.5% | 9.9% | 16.0% | 16.9% | 14.0% | 6.7% | 13.9% | 14.6% | |
| 95.4% | 92.1% | 86.9% | 89.6% | 73.7% | 70.4% | 70.5% | 88.4% | 13.0% | 62.1% | 64.2% | 100.0% | 99.6% | 95.8% | 99.5% | 99.1% | 93.9% | 92.6% | 92.7% | 90.4% | 93.8% | 93.2% | 93.5% | 90.1% | 84.0% | 83.1% | 86.0% | 93.3% | 86.1% | 85.4% | |
| 117.4% | 84.0% | 96.9% | 130.1% | 94.9% | 416.6% | 568.2% | 236.6% | 78.2% | 208.4% | 192.5% | 152.1% | 116.6% | 101.4% | 106.6% | 118.8% | 45.4% | 40.9% | 45.1% | 39.5% | 42.2% | 35.3% | 32.6% | 38.6% | 29.4% | 16.3% | 25.1% | 33.8% | 36.8% | 40.8% | |
| 24.5% | 17.5% | 15.2% | 18.6% | 14.0% | 43.7% | 57.0% | 25.7% | 9.8% | 38.5% | 40.8% | 30.3% | 20.7% | 14.0% | 14.2% | 26.3% | 15.3% | 15.7% | 17.9% | 20.4% | 24.2% | 22.5% | 23.2% | 23.3% | 15.8% | 11.4% | 17.4% | 19.5% | 20.8% | 18.8% | |
| 167.2% | 114.8% | 119.9% | 158.6% | 116.4% | 460.3% | 625.2% | 262.3% | 9.8% | 246.8% | 233.3% | 182.4% | 137.3% | 115.3% | 120.8% | 145.1% | 60.7% | 56.5% | 63.0% | 59.9% | 66.5% | 57.8% | 55.8% | 62.0% | 42.0% | 27.4% | 41.7% | 53.9% | 58.0% | 60.4% | |
| -71.8% | -22.7% | -32.7% | -69.0% | -42.6% | -389.9% | -554.6% | -173.9% | 3.2% | -188.0% | -169.1% | -91.5% | -37.7% | -19.5% | -21.2% | -46.0% | 33.2% | 36.1% | 29.7% | 30.5% | 27.4% | 35.4% | 37.8% | 28.1% | 42.1% | 55.7% | 44.2% | 30.9% | 28.1% | 24.9% | |
| 59.3% | 10.3% | 11.5% | 2.9% | 7.7% | 55.3% | 42.9% | 7.8% | 27.7% | 62.0% | 26.1% | 9.6% | 3.3% | 0.6% | 2.0% | 4.8% | 3.3% | 2.2% | 1.3% | 0.3% | 0.1% | 0.4% | 0.4% | 0.4% | 0.7% | 0.4% | 0.5% | 0.6% | 0.4% | 0.3% | |
| -71.8% | -22.7% | -21.5% | -66.1% | -50.4% | -334.6% | -511.7% | -166.1% | 31.0% | 188.0% | -143.6% | -74.8% | -33.7% | -19.0% | -22.8% | -50.0% | 30.1% | 33.9% | 27.5% | 29.9% | 27.4% | 35.4% | 38.1% | 30.9% | 44.8% | 58.0% | 39.9% | 32.0% | 33.7% | 36.5% | |
| 122.0% | 22.7% | -22.0% | -4.9% | 4.2% | -98.6% | -31.9% | 5.2% | -48.4% | 270.2% | -34.5% | -23.8% | 1.0% | -1.1% | -0.5% | -0.3% | -24.4% | 13.7% | 15.2% | 14.4% | 8.9% | 15.0% | 1.6% | 4.0% | 3.5% | 7.8% | 4.3% | 1.9% | 2.6% | 5.1% | |
| -134.4% | -35.0% | -22.5% | -67.0% | -39.2% | -346.7% | -565.7% | -186.9% | 24.0% | -144.2% | -161.3% | -84.5% | -34.7% | -17.9% | -22.8% | -49.7% | 54.4% | 20.2% | 12.3% | 15.5% | 18.4% | 20.4% | 36.4% | 26.9% | 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% | |
| -46.5% | -28.1% | -24.9% | -59.1% | -35.2% | -362.3% | -516.2% | -159.2% | 39.8% | -102.6% | -120.6% | -65.6% | -32.9% | -14.6% | -16.9% | -39.0% | 35.9% | 38.1% | 31.6% | 32.3% | 29.5% | 37.9% | 40.0% | 30.8% | 48.3% | 60.2% | 43.2% | 30.9% | 37.4% | 40.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.